TheraRadar
Clinical-Stage Companies / Anterogen

Anterogen

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 10/22/2024

17
Total Trials
3
Phase 3
8
Phase 2
3
Recruiting
133
Score

Pipeline by Phase

Phase 3
3
Phase 2
8
Phase 1
8

Therapeutic Focus

Diabetic Foot Ulcer Crohn's Fistula Dystrophic Epidermolysis Bullosa Osteoarthritis, Knee Crohn

Clinical Trials (17)

NCT04612465 Phase 3 ACTIVE NOT RECRUITING

Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula

Started: 1/9/2020

NCT04569409 Phase 3 COMPLETED

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.

Started: 7/14/2020

NCT03370874 Phase 3 COMPLETED

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.

Started: 6/27/2018

NCT05157958 Phase 2 RECRUITING

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

Started: 5/1/2023

NCT03754465 Phase 2 COMPLETED

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

Started: 1/2/2019

NCT02619851 Phase 2 COMPLETED

A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects

Started: 12/23/2015

NCT02619877 Phase 2 COMPLETED

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers

Started: 10/1/2015

NCT01314092 Phase 2 TERMINATED

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Started: 1/1/2011

NCT01011244 Phase 2 COMPLETED

Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula

Started: 2/1/2010

NCT06539429 Phase 1 ACTIVE NOT RECRUITING

Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L

Started: 10/22/2024

NCT01440699 Phase 1 COMPLETED

Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula

Started: 9/1/2011

NCT02579369 Phase 1 COMPLETED

Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Started: 12/8/2015

NCT02131077 Phase 1 COMPLETED

Safety and Efficacy Study of Allogeneic Adipose-derived Stem Cells for Treatment of Lateral Epicondylitis

Started: 1/1/2014

NCT02394873 Phase 1 COMPLETED

A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound

Started: 3/1/2015

NCT02394886 Phase 1 COMPLETED

Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers

Started: 11/1/2014

NCT01739530 Phase 1 COMPLETED

Safety of Repaircell in Healthy Volunteers

Started: 3/1/2009

NCT00992485 Phase 1 COMPLETED

Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula

Started: 11/1/2008

Drug Candidates

ASC Fibringlue ANT-301 ALLO-ASC-DFU ALLO-ASC-SHEET Allogenic human adipose-derived stem cells ALLO-ASC-TI Placebo Autologous cultured adipose derived stem cells(low dose group) Autologous cultured adipose derived stem cells(high dose group)
Activity Status: Slowing
Last Trial Started: 10/22/2024
Last Trial Ended: 12/5/2024
Trials (12 months): 0
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.